BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 17, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/14 cls
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Roth Capital Partners Scott Henry New Buy 13% $5.84
Henry set a $10 target ahead of the Dec. 21 PDUFA date for Alexza's Adasuve Staccato loxapine to treat agitation in adult patients with schizophrenia or bipolar disorder. Henry expects a positive outcome based on correspondence from the agency indicating that manufacturing is the last hurdle and his belief the agency is comfortable with the product's benefit/risk profile. He estimates peak annual revenues of $200-$250M. On Friday, EMA's CHMP issued a positive opinion recommending approval in Europe.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Piper Jaffray Edward Tenthoff Upgrade Overweight (from neutral) 11% $18.54
Tenthoff also raised his target to $25 from $19 ahead of upcoming milestones, including data next summer from a Phase II trial of ALN-TTR02 for amyloidosis. He noted Alnylam can now focus on its RNAi products and new partnerships after settling litigation with Tekmira Pharmaceuticals...

Read the full 1028 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >